3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Barrett Esophagus
13
Esophageal Neoplasms
7
Rectal Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma Of Esophagus
6
Nasopharyngeal Carcinoma
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Polyps
3
Lung Neoplasms
3
Precancerous Conditions
2
Pathologic Complete Response
2
Hyperplasia
2
Gastroesophageal Reflux
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Adenomatous Polyposis Coli
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Upper Tract Urothelial Carcinoma
1
Thyroid Neoplasms
1
Stomach Ulcer
1
Stomach Diseases
1
Recurrence
1
Polyposis, Gastric
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Metaplasia
1
Interventions
pembrolizumab
1
camrelizumab
1
apatinib
1
Surgical Procedures, Operative
1
Ocoxin
1
Everolimus
1
Endoscopy
1
Capecitabine
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Diseases
×
Endoscopy
×
Clear all
NCT02219529
2015-07-21
MCE
Changhai Hospital
Phase 3
Completed
350 enrolled